On the horizon: upcoming new agents for the management of ITP

2.

Imbach

P

,

Barandun

S

,

d'Apuzzo

V

, et al.

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

.

Lancet

.

1981

;

1

(

8232

):

1228

-

1231

.

3.

de Barros Torelli

DFH

,

Oliveira

CBS

,

Nai

GA

,

Trindade

EM

,

Prestes-Carneiro

LE

.

Eltrombopag for adults and children with immune-refractory thrombocytopenic purpura: a systematic review

.

J Clin Med

.

2023

;

12

(

12

).

4.

Shen

N

,

Qiao

J

,

Jiang

Y

, et al.

Safety of non‑peptide thrombopoietin receptor agonists in patients with immune thrombocytopenia: a systematic review and meta‑analysis of short‑term double‑blind randomized clinical trials

.

Exp Ther Med

.

2023

;

26

(

2

):

393

.

5.

Britto

J

,

Holbrook

A

,

Sun

H

, et al.

Thrombopoietin receptor agonists and other second-line therapies for immune thrombocytopenia: a narrative review with a focus on drug access in Canada

.

Clin Invest Med

.

2024

;

47

(

1

):

13

-

22

.

6.

Madkhali

MA

.

Recent advances in the management of immune thrombocytopenic purpura (ITP): a comprehensive review

.

Medicine (Baltimore)

.

2024

;

103

(

3

):

e36936

.

7.

Provan

D

,

Semple

JW

.

Recent advances in the mechanisms and treatment of immune thrombocytopenia

.

EBioMedicine

.

2022

;

76

:

103820

.

8.

Rozkiewicz

D

,

Hermanowicz

JM

,

Kwiatkowska

I

,

Krupa

A

,

Pawlak

D.

Bruton's tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials

.

Molecules

.

2023

;

28

(

5

).

9.

Alu

A

,

Lei

H

,

Han

X

,

Wei

Y

,

Wei

X.

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

.

J Hematol Oncol

.

2022

;

15

(

1

):

138

.

10.

Kuter

DJ

,

Efraim

M

,

Mayer

J

, et al.

Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia

.

N Engl J Med

.

2022

;

386

(

15

):

1421

-

1431

.

11.

Kuter

DJ

,

Mayer

J

,

Efraim

M

, et al.

Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia

.

Blood Adv

.

2024

;

8

(

7

):

1715

-

1724

.

12.

Tullemans

BME

,

Karel

MFA

,

Léopold

V

, et al.

Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function

.

EJHaem

.

2021

;

2

(

4

):

685

-

699

.

13.

Denzinger

V

,

Busygina

K

,

Jamasbi

J

, et al.

Optimizing platelet GPVI inhibition versus haemostatic impairment by the Btk inhibitors ibrutinib, acalabrutinib, ONO/GS-4059, BGB-3111 and evobrutinib

.

Thromb Haemost

.

2019

;

119

(

3

):

397

-

406

.

14.

Aguilar

C.

Ibrutinib-related bleeding: pathogenesis, clinical implications and management

.

Blood Coagul Fibrinolysis

.

2018

;

29

(

6

):

481

-

487

.

15.

Provan

D

,

Arnold

DM

,

Bussel

JB

, et al.

Updated international consensus report on the investigation and management of primary immune thrombocytopenia

.

Blood Adv

.

2019

;

3

(

22

):

3780

-

3817

.

16.

Singh

A

,

Uzun

G

,

Bakchoul

T.

Primary immune thrombocytopenia: novel insights into pathophysiology and disease management

.

J Clin Med

.

2021

;

10

(

4

).

17.

Lozano

NA

,

Lozano

A

,

Marini

V

, et al.

Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns

.

Am J Reprod Immunol

.

2018

;

80

(

3

):

e12972

.

18.

Akilesh

S

,

Christianson

GJ

,

Roopenian

DC

,

Shaw

AS

.

Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism

.

J Immunol

.

2007

;

179

(

7

):

4580

-

4588

.

19.

Newland

AC

,

Sánchez-González

B

,

Rejtő

L

, et al.

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

.

Am J Hematol

.

2020

;

95

(

2

):

178

-

187

.

20.

Robak

T

,

Kaźmierczak

M

,

Jarque

I

, et al.

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

.

Blood Adv

.

2020

;

4

(

17

):

4136

-

4146

.

21.

Najaoui

A

,

Bakchoul

T

,

Stoy

J

, et al.

Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)

.

Eur J Haematol

.

2012

;

88

(

2

):

167

-

174

.

22.

Nikitin

PA

,

Rose

EL

,

Byun

TS

,

Parry

GC

,

Panicker

S.

C1s inhibition by BIVV009 (Sutimlimab) prevents complement-enhanced activation of autoimmune human B cells in vitro

.

J Immunol

.

2019

;

202

(

4

):

1200

-

1209

.

23.

Broome

CM

,

Röth

A

,

Kuter

DJ

, et al.

Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia

.

Blood Adv

.

2023

;

7

(

6

):

987

-

996

.

24.

Jang

JH

,

Wong

L

,

Ko

B-S

, et al.

Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of- concept study

.

Blood Adv

.

2022

;

6

(

15

):

4450

-

4460

.

25.

Bomback

AS

,

Kavanagh

D

,

Vivarelli

M

, et al.

Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy- study design of the APPEAR-C3G trial

.

Kidney Int Rep

.

2022

;

7

(

10

):

2150

-

2159

.

26.

Bennett

CM

,

Rogers

ZR

,

Kinnamon

DD

, et al.

Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura

.

Blood

.

2006

;

107

(

7

):

2639

-

2642

.

27.

Morandi

F

,

Horenstein

AL

,

Costa

F

,

Giuliani

N

,

Pistoia

V

,

Malavasi

F.

CD38: a target for immunotherapeutic approaches in multiple myeloma

.

Front Immunol

.

2018

;

9

:

2722

.

28.

Conti

F

,

Gottardi

F

,

Moratti

M

, et al.

Refractory immune thrombocytopenia successfully treated with bortezomib in a child with 22q11.2 deletion syndrome, complicated by Evans syndrome and hypogammaglobulinemia

.

Platelets

.

2022

;

33

(

5

):

801

-

806

.

29.

Li

G

,

Wang

S

,

Li

N

, et al.

Proteasome inhibition with bortezomib induces apoptosis of long-lived plasma cells in steroid-resistant or relapsed immune thrombocytopaenia

.

Thromb Haemost

.

2018

;

118

(

10

):

1752

-

1764

.

30.

Beckman

JD

,

Rollins-Raval

MA

,

Raval

JS

,

Park

YA

,

Mazepa

M

,

Ma

A.

Bortezomib for refractory immune-mediated thrombocytopenia purpura

.

Am J Ther

.

2018

;

25

(

2

):

e270

-

e272

.

31.

Mahévas

M

,

Azzaoui

I

,

Crickx

E

, et al.

Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial

.

Haematologica

.

2021

;

106

(

9

):

2449

-

2457

.

32.

Patel

VL

,

Schwartz

J

,

Bussel

JB

.

The effect of anti-CD40 ligand in immune thrombocytopenic purpura

.

Br J Haematol

.

2008

;

141

(

4

):

545

-

548

.

33.

Hoffmeister

KM

,

Falet

H.

Platelet clearance by the hepatic Ashwell- Morrell receptor: mechanisms and biological significance

.

Thromb Res

.

2016

;

141

(

suppl 2

):

S68

-

S72

.

34.

Colunga-Pedraza

PR

,

Peña-Lozano

SP

,

Sánchez-Rendón

E

, et al.

Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature

.

J Thromb Thrombolysis

.

2022

;

54

(

2

):

360

-

366

.

35.

Teachey

DT

,

Greiner

R

,

Seif

A

, et al.

Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome

.

Br J Haematol

.

2009

;

145

(

1

):

101

-

106

.

36.

Bride

KL

,

Vincent

T

,

Smith-Whitley

K

, et al.

Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial

.

Blood

.

2016

;

127

(

1

):

17

-

28

.

37.

Patel

DD

,

Bussel

JB

.

Neonatal Fc receptor in human immunity: function and role in therapeutic intervention

.

J Allergy Clin Immunol

.

2020

;

146

(

3

):

467

-

478

.